Repligen | RGEN - Debt


Repligen reported $546.58M in Debt for its fiscal quarter ending in March of 2026.





Debt Change Date
Agilent USD 3.35B 0 Dec/2025
Align Technology USD 114.45M 6.82M Dec/2025
Bio Techne USD 200M 60M Mar/2026
BioMarin Pharmaceutical USD 1.44B 833.74M Mar/2026
Bristol-Myers Squibb USD 47.14B 3.9B Dec/2025
Bruker USD 2.04B 34.4M Dec/2025
Charles River Laboratories USD 2.57B 58.23M Dec/2025
Danaher USD 18.48B 66M Mar/2026
Dentsply International USD 2.33B 137M Mar/2026
General Electric Aerospace USD 20.28B 217M Mar/2026
Henry Schein USD 3.75B 313M Mar/2026
Illumina USD 2.55B 23M Dec/2025
IQVIA Holdings USD 15.83B 109M Mar/2026
Mettler Toledo International USD 2.15B 57.69M Dec/2025
Myriad Genetics USD 59.3M 19.7M Mar/2025
OraSure Technologies USD 782K 465K Jun/2024
Pacific Biosciences Of California USD 892.24M 653K Dec/2023
Pfizer USD 63.73B 231M Mar/2026
Repligen USD 546.58M 4.37M Mar/2026
Revvity USD 3.4B 29.2M Dec/2025
Standard Biotools USD 27.39M 1.23M Sep/2025
Thermo Fisher Scientific USD 39.39B 3.7B Dec/2025
Waters USD 1.49B 4.92M Dec/2025
West Pharmaceutical Services USD 202.8M 0 Mar/2026